Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3928772 | 0.99 | HSD11B1 (0.53) | HSD11B1ALOX15L3MBTL1HSD17B10SMN1; SMN2 | |
| SCHEMBL3918650 | 0.89 | L3MBTL1 (0.50) | HSD11B1ALOX15L3MBTL1HSD17B10SMN1; SMN2 | |
| SCHEMBL14342610 | 0.84 | ALOX15 (0.52) | ALOX15L3MBTL1SMN1; SMN2EPHX2GAA | |
| SCHEMBL3918142 | 0.80 | ALOX15 (0.52) | ALOX15SMN1; SMN2EPHX2GAATSHR | |
| Hydrochloric Acid SCHEMBL3928778 | 0.79 | ALOX15 (0.51) | ALOX15SMN1; SMN2EPHX2GAATSHR | |
| SCHEMBL4516086 | 0.75 | L3MBTL1 (0.65) | HSD11B1L3MBTL1HSD17B10SMN1; SMN2EPHX2 | |
| SCHEMBL13609055 | 0.73 | LMNA (0.52) | HSD11B1ALOX15L3MBTL1HSD17B10SMN1; SMN2 | |
| SCHEMBL3923876 | 0.73 | CYP2C19 (0.49) | HSD11B1L3MBTL1HSD17B10EPHX2GAA | |
| SCHEMBL4526442 | 0.72 | L3MBTL1 (0.59) | HSD11B1L3MBTL1HSD17B10EPHX2GAA | |
| SCHEMBL5158497 | 0.72 | HSD11B1 (0.68) | HSD11B1L3MBTL1HSD17B10SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | HSD11B1 1/4885ALOX15 354/4885L3MBTL1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.